
July 12, 2016 Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition

July 12, 2016 Manufacturing and Production, Research and Development aldoxorubicin, cytrx

July 12, 2016 Manufacturing and Production, Sales and Marketing Amgen, FDA, Repatha, pushtronex

July 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Coherus BioSciences, biosimilar, drug trial

July 12, 2016 Manufacturing and Production, Sales and Marketing FDA, Shire, dry eye, xiidra

July 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

July 11, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Medivation, XBiotech, juno therapeutics, markets, stocks
July 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
July 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

July 5, 2016 Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese
July 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

July 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks
June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation

June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing EMA, Novo Nordisk, insulin pump, marketing, product launch
June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation